Travaux scientifiques

Prof. Dr. Yeşim Eralp

193 publications. La source de l’information est indiquée à côté de chaque publication.

Retour au profil

  1. Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients

    Plos One, 2019

    DOI 10.1371/journal.pone.0226853 PMID 31860648 46 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  2. Preoperative Therapy for Operable Breast Cancer

    Springer eBooks, 2019

    DOI 10.1007/978-3-030-16792-9_13 Source : OpenAlex

  3. Impact of Personality Traits, Anxiety, Depression and Hopelessness Levels on Quality of Life in the Patients with Breast Cancer

    European Journal of Breast Health, 2018

    DOI 10.5152/ejbh.2018.3724 PMID 29774319 42 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  4. Possible role of stress, coping strategies, and life style in the development of breast cancer

    The International Journal of Psychiatry in Medicine, 2018

    DOI 10.1177/0091217417749789 PMID 29292669 6 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  5. Prognostic Significance of Adjuvant Chemotherapy Induced Amenorrhea in Luminal A and B Subtypes

    European Journal of Breast Health, 2018

    DOI 10.5152/ejbh.2018.3808 PMID 30123884 3 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  6. P1.01-45 Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey

    Journal of Thoracic Oncology, 2018

    DOI 10.1016/j.jtho.2018.08.601 Texte intégral en libre accèsSource : OpenAlex

  7. The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey

    Annals of Oncology, 2018

    DOI 10.1093/annonc/mdy292.023 Texte intégral en libre accèsSource : OpenAlex

  8. Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey

    BioRxiv, 2018

    Source : ORCID

  9. Long-term effective local control in patients presenting with T4 disease and treated with breast-conserving therapy after neoadjuvant chemotherapy

    Annals of Surgical Oncology, 2018

    Source : ORCID

  10. Preoperative Systemic Therapy for Operable Breast Cancer

    Springer eBooks, 2018

    DOI 10.1007/978-3-319-96947-3_9 Source : OpenAlex

  11. Preoperative Lymphedema-Related Risk Factors in Early-Stage Breast Cancer

    Lymphatic Research and Biology, 2017

    DOI 10.1089/lrb.2016.0045 PMID 28346852 32 citations (Europe PMC) Source : OpenAlex

  12. Roles of Biopsychosocial Factors in the Development of Breast Cancer

    European Journal of Breast Health, 2017

    DOI 10.5152/ejbh.2017.3519 PMID 29082379 7 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  13. The prognostic impact of chemotherapy induced amenorrhea in women treated with early stage breast cancer

    Annals of Oncology, 2017

    DOI 10.1093/annonc/mdx362.022 Texte intégral en libre accèsSource : OpenAlex

  14. Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients.

    PubMed, 2016

    PMID 28039703 11 citations (Europe PMC) Source : OpenAlex

  15. True Local Recurrences after Breast Conserving Surgery have Poor Prognosis in Patients with Early Breast Cancer

    Cureus, 2016

    DOI 10.7759/cureus.541 PMID 27158571 6 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  16. The Prognostic Impact of Molecular Subtypes and Very Young Age on Breast Conserving Surgery in Early Stage Breast Cancer

    Cureus, 2016

    DOI 10.7759/cureus.633 PMID 27433412 4 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  17. The Relationship between Bone Mineral Density and Estrogen Receptor Positivity in Patients with Breast Cancer

    Meme sağlığı dergisi/Meme sağlığı dergisi, 2016

    DOI 10.5152/tjbh.2016.2961 PMID 28331747 Texte intégral en libre accèsSource : OpenAlex

  18. Follow-up of chemotherapy induced changes in anti-Mullerian hormone, antral follicle number and ovary volume in premenopausal breast cancer patients

    Annals of Oncology, 2016

    DOI 10.1093/annonc/mdw364.59 Texte intégral en libre accèsSource : OpenAlex

  19. İleri Evre Over Kanseri Tedavisinde Hedefe Yönelik Tedavilerin Güncel Yeri

    Turkiye Klinikleri Medical Oncology - Special Topics, 2016

    Source : OpenAlex

  20. The Role of Genomic Profiling in Advanced Breast Cancer: The Two Faces of Janus

    Translational Oncogenomics, 2016

    DOI 10.4137/tog.s39410 PMID 27547031 3 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  21. Preoperative Therapy for Operable Breast Cancer

    Breast Disease, 2016

    DOI 10.1007/978-3-319-26012-9_13 5 citations (OpenAlex) Source : ORCID

  22. Concomitant etoposide and cisplatin provided improved survival compared with docetaxel and cisplatin in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy

    Medicine, 2016

    DOI 10.1097/md.0000000000004280 PMID 27472701 13 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  23. Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients

    Journal of B.U.ON., 2016

    Source : ORCID

  24. The role of genomic profiling in advanced breast cancer: The two faces of Janus

    Translational Oncogenomics, 2016

    DOI 10.4137/togog.s39410 Source : ORCID

  25. Is Administration of Trastuzumab an Independent Risk Factor for Developing Osteonecrosis of the Jaw Among Metastatic Breast Cancer Patients Under Zoledronic Acid Treatment?

    Medicine, 2015

    DOI 10.1097/md.0000000000000671 PMID 25950681 14 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  26. 1967 Does adjuvant chemotherapy induced amenorrhea effect survival in operated premenopausal breast cancer patients?

    European Journal of Cancer, 2015

    DOI 10.1016/s0959-8049(16)30915-7 Source : OpenAlex

  27. Clinicopathological Data's of Advanced NSCLC Patients with ROS1 Gene Rearrangement and of Clinical Responses to Crizotinib in TURKEY

    BioRxiv, 2015

    Source : ORCID

  28. Concomitant Chemoradiotherapy with Etoposide & Cisplatin versus Docetaxel & Cisplatin in Locally Advanced Non-Small Cell Lung Cancer

    Journal of Thoracic Oncology, 2015

    Source : ORCID

  29. Metaplastic Breast Carcinoma Versus Triple-Negative Breast Cancer Survival and Response to Treatment

    Medicine, 2015

    DOI 10.1097/md.0000000000002341 PMID 26717372 61 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  30. Prognostic value of receptor status change following neoadjuvant chemotherapy in locally advanced breast cancer

    Cancer Treatment Communications, 2015

    DOI 10.1016/j.ctrc.2015.07.001 8 citations (OpenAlex) Texte intégral en libre accèsSource : ORCID

  31. The effect of internal mammary lymph node biopsy on the therapeutic decision and survival of patients with breast cancer

    European Journal of Surgical Oncology (EJSO), 2015

    DOI 10.1016/j.ejso.2015.07.005 PMID 26210653 9 citations (Europe PMC) Source : ORCID

  32. The Outcome of Patients with Triple Negative Breast Cancer: The Turkish Oncology Group Experience

    Meme sağlığı dergisi/Meme sağlığı dergisi, 2014

    DOI 10.5152/tjbh.2014.1904 PMID 28331673 7 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  33. Is there any diagnostic value of serum protease-activated receptor-1 (PAR1) levels on determination of epithelial ovarian carcinoma?

    Tumor Biology, 2014

    DOI 10.1007/s13277-013-1567-4 PMID 24390664 3 citations (Europe PMC) Source : OpenAlex

  34. Abundant circulating microRNAs in breast cancer patients fluctuate considerably during neoadjuvant chemotherapy

    Oncology Letters, 2014

    DOI 10.3892/ol.2014.2188 PMID 25009660 15 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  35. Magnetic resonance imaging as a predictor of pathologic response rates in patients treated with neoadjuvant chemotherapy

    European Journal of Cancer, 2014

    Source : ORCID

  36. Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG)

    Breast Cancer, 2013

    DOI 10.1007/s12282-013-0506-y PMID 24338610 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  37. A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer

    Cancer Chemotherapy and Pharmacology, 2013

    DOI 10.1007/s00280-013-2212-z PMID 23801282 3 citations (Europe PMC) Source : OpenAlex

  38. Predictive Role of Midtreatment Changes in Survivin, GSTP1, and Topoisomerase 2α Expressions for Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer

    American Journal of Clinical Oncology, 2013

    DOI 10.1097/coc.0b013e318243913f PMID 22441341 8 citations (Europe PMC) Source : ORCID

  39. Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: A multicentric Turkish Oncology Group (TOG) trial

    The Breast, 2013

    DOI 10.1016/j.breast.2013.07.048 PMID 23954396 4 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  40. The predictive and prognostic role of tumoral miRNA expression levels in patients with breast cancer (BC) treated with neoadjuvant chemotherapy (NAC)

    Cancer Research, 2013

    DOI 10.1158/0008-5472.sabcs13-p4-07-08 Source : ORCID

  41. Which cytologically proven node-positive breast cancer patients can avoid axillary lymph dissection after neaodjuvant chemotherapy?

    Cancer Research, 2013

    DOI 10.1158/0008-5472.sabcs13-p1-01-22 Source : ORCID

  42. 57PD NEOADJUVANT CHEMORADIOTHERAPY FOR LOCALLY ADVANCED NON SMALL CELL LUNG CANCER

    Lung Cancer, 2013

    DOI 10.1016/s0169-5002(13)70278-2 Source : OpenAlex

  43. Association of clinical and pathological variables with survival in thymoma

    Medical Oncology, 2012

    DOI 10.1007/s12032-011-0101-z PMID 22057358 10 citations (Europe PMC) Source : ORCID

  44. Phase II Study of Loading-Dose Ibandronate Treatment in Patients with Breast Cancer and Bone Metastases Suffering from Moderate to Severe Pain

    Onkologie, 2012

    DOI 10.1159/000338369 PMID 22868504 9 citations (Europe PMC) Source : ORCID

  45. PO-0707 THE EFFECTS OF CONCOMITANT CHEMORADIATION ON DISEASE CONTROL AND SURVIVAL IN CERVIX CARCINOMA

    Radiotherapy and Oncology, 2012

    DOI 10.1016/s0167-8140(12)71040-x Source : OpenAlex

  46. Guidelines for Authors

    Onkologie, 2012

    DOI 10.1159/000257462 Source : OpenAlex

  47. PharmaNews / PharmaTicker

    Onkologie, 2012

    DOI 10.1159/000239969 Texte intégral en libre accèsSource : OpenAlex

  48. Meetings and Conferences · Tagungen und Kongresse

    Onkologie, 2012

    DOI 10.1159/000259394 Texte intégral en libre accèsSource : OpenAlex

  49. Glutathione S-transferase P1 polymorphisms are associated with time to tumor progression in small cell lung cancer patients.

    PubMed, 2011

    PMID 21766492 9 citations (Europe PMC) Source : OpenAlex

  50. Trastuzumab use and survival in HER2 (+) nonmetastatic breast cancer among Turkish women.

    Journal of Clinical Oncology, 2011

    DOI 10.1200/jco.2011.29.27_suppl.56 Source : ORCID